JP2021511808A5 - - Google Patents
Info
- Publication number
- JP2021511808A5 JP2021511808A5 JP2020541916A JP2020541916A JP2021511808A5 JP 2021511808 A5 JP2021511808 A5 JP 2021511808A5 JP 2020541916 A JP2020541916 A JP 2020541916A JP 2020541916 A JP2020541916 A JP 2020541916A JP 2021511808 A5 JP2021511808 A5 JP 2021511808A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- hvr
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023116602A JP7678841B2 (ja) | 2018-02-02 | 2023-07-18 | 抗ｃｔｌａ４抗体ならびにその作製及び使用方法 |
| JP2025076560A JP2025124652A (ja) | 2018-02-02 | 2025-05-02 | 抗ｃｔｌａ４抗体ならびにその作製及び使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2018/075064 WO2019148444A1 (en) | 2018-02-02 | 2018-02-02 | Anti-ctla4 antibodies and methods of making and using the same |
| CNPCT/CN2018/075064 | 2018-02-02 | ||
| PCT/CN2019/074580 WO2019149281A1 (en) | 2018-02-02 | 2019-02-02 | Anti-ctla4 antibodies and methods of making and using the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023116602A Division JP7678841B2 (ja) | 2018-02-02 | 2023-07-18 | 抗ｃｔｌａ４抗体ならびにその作製及び使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021511808A JP2021511808A (ja) | 2021-05-13 |
| JP2021511808A5 true JP2021511808A5 (enExample) | 2022-02-09 |
| JP7413265B2 JP7413265B2 (ja) | 2024-01-15 |
Family
ID=67475181
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020541916A Active JP7413265B2 (ja) | 2018-02-02 | 2019-02-02 | 抗ｃｔｌａ４抗体ならびにその作製及び使用方法 |
| JP2023116602A Active JP7678841B2 (ja) | 2018-02-02 | 2023-07-18 | 抗ｃｔｌａ４抗体ならびにその作製及び使用方法 |
| JP2025076560A Pending JP2025124652A (ja) | 2018-02-02 | 2025-05-02 | 抗ｃｔｌａ４抗体ならびにその作製及び使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023116602A Active JP7678841B2 (ja) | 2018-02-02 | 2023-07-18 | 抗ｃｔｌａ４抗体ならびにその作製及び使用方法 |
| JP2025076560A Pending JP2025124652A (ja) | 2018-02-02 | 2025-05-02 | 抗ｃｔｌａ４抗体ならびにその作製及び使用方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US11359016B2 (enExample) |
| EP (1) | EP3746486A4 (enExample) |
| JP (3) | JP7413265B2 (enExample) |
| KR (2) | KR20250131831A (enExample) |
| CN (2) | CN112352000B (enExample) |
| AU (3) | AU2019214188B2 (enExample) |
| BR (1) | BR112020015385B1 (enExample) |
| CA (1) | CA3089795A1 (enExample) |
| IL (1) | IL276277A (enExample) |
| MX (2) | MX2020008075A (enExample) |
| SG (1) | SG11202007160PA (enExample) |
| TW (1) | TWI829706B (enExample) |
| WO (2) | WO2019148444A1 (enExample) |
| ZA (2) | ZA202005259B (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7173993B2 (ja) | 2017-05-19 | 2022-11-17 | ウーシー バイオロジクス（シャンハイ）カンパニー リミテッド | 細胞傷害性ｔリンパ球関連タンパク質４（ｃｔｌａ－４）に対する新規モノクローナル抗体 |
| WO2019036855A1 (en) | 2017-08-21 | 2019-02-28 | Adagene Inc. | Anti-cd137 molecules and use thereof |
| WO2019148444A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
| WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| KR20210108978A (ko) | 2018-12-21 | 2021-09-03 | 오제 이뮈노테라프틱스 | 이작용성 항-pd-1/il-7 분자 |
| CA3122773A1 (en) | 2018-12-26 | 2020-07-02 | Xilio Development, Inc. | Anti-ctla4 antibodies and methods of use thereof |
| WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
| JP7650047B2 (ja) * | 2019-11-27 | 2025-03-24 | 株式会社 MiyaCare Therapeutics | 変異型結合性タンパク質の製造方法及び変異型ｐｄ－１ |
| WO2021122866A1 (en) | 2019-12-17 | 2021-06-24 | Ose Immunotherapeutics | Bifunctional molecules comprising an il-7 variant |
| UA128549C2 (uk) * | 2019-12-27 | 2024-08-07 | Чугаі Сейяку Кабусікі Кайся | Антитіло до ctla-4 та його застосування |
| JP2023521384A (ja) * | 2020-04-09 | 2023-05-24 | シートムエックス セラピューティクス，インコーポレイテッド | 活性化可能抗体を含む組成物 |
| AR122043A1 (es) * | 2020-05-12 | 2022-08-03 | Bristol Myers Squibb Co | Dosificación y administración del anticuerpo anti-ctla-4 activable |
| EP4559477A3 (en) | 2020-05-13 | 2025-08-13 | Adagene AG | Compositions and methods for treating cancer |
| WO2021226883A1 (en) * | 2020-05-13 | 2021-11-18 | Adagene Ag | Compositions and methods for treating cancer submission of sequence listing on ascii text file |
| JP7620780B2 (ja) * | 2020-06-30 | 2025-01-24 | ノナ・バイオサイエンシーズ・（シャンハイ）・カンパニー・リミテッド | Ｈ２Ｌ２とＨＣＡｂ構造を有する結合タンパク質 |
| TWI861258B (zh) * | 2020-10-21 | 2024-11-11 | 日商中外製藥股份有限公司 | 抗ctla-4抗體及其之用途 |
| WO2022112198A1 (en) | 2020-11-24 | 2022-06-02 | Worldwide Innovative Network | Method to select the optimal immune checkpoint therapies |
| WO2022212286A1 (en) * | 2021-03-28 | 2022-10-06 | Peter Peizhi Luo | Methods for treating cancer using anti-ctla4 antibodies |
| MX2023011964A (es) | 2021-04-09 | 2024-01-08 | Ose Immunotherapeutics | Nuevo andamio para moléculas bifuncionales con propiedades mejoradas. |
| EP4320156A1 (en) | 2021-04-09 | 2024-02-14 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
| JP2024517381A (ja) * | 2021-04-11 | 2024-04-22 | アダジーン インコーポレイテッド | がんを治療するための併用療法 |
| US12448451B2 (en) | 2021-06-25 | 2025-10-21 | Chugai Seiyaku Kabushiki Kaisha | Anti-CTLA-4 antibody and use thereof |
| IL312728A (en) * | 2021-11-30 | 2024-07-01 | Daiichi Sankyo Co Ltd | Protease-cleavable masked antibodies |
| WO2024003360A1 (en) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarkers and uses thereof for the treatment of neuroblastoma |
| JP2025525886A (ja) | 2022-08-02 | 2025-08-07 | オーエスイー・イミュノセラピューティクス | Ｃｄ２８に対する多機能性分子 |
| EP4581058A2 (en) * | 2022-08-30 | 2025-07-09 | Adagene Pte. Ltd. | Methods for treating cancer using anti-ctla4 antibodies |
| EP4583981A2 (en) * | 2022-09-09 | 2025-07-16 | Adagene Pte. Ltd. | Activatable anti-ctla4 antibodies for treating cancer |
| EP4687991A1 (en) | 2023-03-30 | 2026-02-11 | Ose Immunotherapeutics | Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof |
| WO2024200820A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Method of synthesis of targeted lipid nanoparticle and uses thereof |
| WO2024212152A1 (en) * | 2023-04-13 | 2024-10-17 | Adagene Pte. Ltd. | Anti-ctla4 antibodies and methods of making and using the same |
| WO2025242835A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of cancer |
| WO2026068705A1 (en) | 2024-09-26 | 2026-04-02 | Ose Immunotherapeutics | Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| US7018809B1 (en) | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
| DE69233408T2 (de) | 1991-12-02 | 2005-09-22 | Cambridge Antibody Technology Ltd., Melbourn | Herstellung von Antikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken. |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US6765087B1 (en) | 1992-08-21 | 2004-07-20 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| ES2162863T3 (es) | 1993-04-29 | 2002-01-16 | Unilever Nv | Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae. |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5994619A (en) | 1996-04-01 | 1999-11-30 | University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus | Production of chimeric bovine or porcine animals using cultured inner cell mass cells |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| ES2248127T3 (es) | 1999-10-04 | 2006-03-16 | Medicago Inc. | Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno. |
| ME00502B (me) | 2001-01-05 | 2011-10-10 | Amgen Fremont Inc | Antitjela za insulinu sličan receptor faktora i rasta |
| KR100983997B1 (ko) | 2001-01-09 | 2010-09-28 | 메르크 파텐트 게엠베하 | 수용체 타이로신 키나아제 저해제 및 혈관형성 저해제를 사용하는 병용 요법 |
| DK1399484T3 (da) | 2001-06-28 | 2010-11-08 | Domantis Ltd | Dobbelt-specifik ligand og anvendelse af denne |
| ATE411054T1 (de) | 2001-08-17 | 2008-10-15 | Coley Pharm Gmbh | Kombinations-motif-immunstimulierende oligonukleotide mit verbesserter wirkung |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| US7771951B2 (en) | 2001-12-03 | 2010-08-10 | Amgen Fremont Inc. | Antibody categorization based on binding characteristics |
| WO2003074678A2 (en) | 2002-03-01 | 2003-09-12 | Dyax Corp. | Modular recombinatorial display libraries |
| AU2003244817B2 (en) | 2002-06-28 | 2010-08-26 | Domantis Limited | Antigen-binding immunoglobulin single variable domains and dual-specific constructs |
| AR040996A1 (es) | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | Acidos nucleicos inmunoestimuladores |
| EP1578801A2 (en) | 2002-12-27 | 2005-09-28 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
| US20090005257A1 (en) | 2003-05-14 | 2009-01-01 | Jespers Laurent S | Process for Recovering Polypeptides that Unfold Reversibly from a Polypeptide Repertoire |
| DE602004017726D1 (de) | 2003-06-30 | 2008-12-24 | Domantis Ltd | Pegylierte Single-domain-antikörper (dAb) |
| WO2006055697A2 (en) | 2004-11-17 | 2006-05-26 | Board Of Regents, The University Of Texas System | Cancer immunotherapy incorporating p53 |
| DE102004063494A1 (de) | 2004-12-23 | 2006-07-13 | Tegenero Ag | Antikörper |
| AU2005325801A1 (en) | 2005-01-31 | 2006-08-03 | Ablynx N.V. | Method for generating variable domain sequences of heavy chain antibodies |
| MX2007011767A (es) * | 2005-03-23 | 2007-10-18 | Pfizer Prod Inc | Terapia de combinacion de anticuerpo anti-ctla4 e indolinona para el tratamiento del cancer. |
| JP2008542354A (ja) | 2005-06-03 | 2008-11-27 | ファイザー・プロダクツ・インク | 癌治療におけるｅｒｂＢ２阻害剤と他の治療薬の併用 |
| JP5256042B2 (ja) | 2005-11-22 | 2013-08-07 | インサイト・コーポレイション | 癌の処置のための併用療法 |
| CA2631184A1 (en) | 2005-11-28 | 2007-05-31 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| CA2696460A1 (en) | 2007-08-13 | 2009-02-19 | Pfizer Inc. | Combination motif immune stimulatory oligonucleotides with improved activity |
| US20090304719A1 (en) | 2007-08-22 | 2009-12-10 | Patrick Daugherty | Activatable binding polypeptides and methods of identification and use thereof |
| AU2013202755B2 (en) | 2007-08-22 | 2016-05-12 | Cytomx Therapeutics, Inc. | Activatable binding polypeptides and methods of identification and use thereof |
| ES2336873B1 (es) | 2007-11-07 | 2011-01-24 | Proyecto De Biomedicina Cima, S.L. | Composicion farmaceutica para el tratamiento de cancer. |
| PT2594590E (pt) | 2007-12-14 | 2015-01-14 | Bristol Myers Squibb Co | Moléculas de ligação ao recetor humano ox40 |
| RU2636046C2 (ru) | 2009-01-12 | 2017-11-17 | Сайтомкс Терапьютикс, Инк | Композиции модифицированных антител, способы их получения и применения |
| EP2863948B1 (en) | 2012-06-22 | 2018-10-24 | Cytomx Therapeutics Inc. | Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof |
| CN105247050B (zh) | 2013-03-14 | 2020-06-16 | 天演药业 | 用于文库构建、亲和力结合剂筛选和其表达的整合系统 |
| NZ718283A (en) | 2013-09-25 | 2022-05-27 | Cytomx Therapeutics Inc | Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof |
| CA2955947A1 (en) | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
| CN105296433B (zh) * | 2014-08-01 | 2018-02-09 | 中山康方生物医药有限公司 | 一种ctla4抗体、其药物组合物及其用途 |
| ES2789351T3 (es) | 2015-01-13 | 2020-10-26 | Hope City | Máscaras de enlace peptídico de proteínas de unión a CTLA4 |
| MA41374A (fr) | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
| EP3256165B1 (en) | 2015-02-13 | 2021-07-14 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind ctla4 |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| IL292798A (en) | 2015-05-04 | 2022-07-01 | Cytomx Therapeutics Inc | Anti-cd166 antibodies, activatable anti-cd166 antibodies, preparations containing them and their uses |
| CA2984892A1 (en) | 2015-05-04 | 2016-11-10 | Cytomx Therapeutics, Inc. | Anti-itga3 antibodies, activatable anti-itga3 antibodies, and methods of use thereof |
| US20160362469A1 (en) | 2015-06-12 | 2016-12-15 | Tianxin Wang | Methods for protein modification in pharmaceutical applications |
| MX383464B (es) * | 2015-07-13 | 2025-03-14 | Cytomx Therapeutics Inc | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos. |
| ES2979210T3 (es) | 2015-12-15 | 2024-09-24 | Oncoc4 Inc | Anticuerpos monoclonales anti-CTLA4 humano quiméricos y humanizados y usos de los mismos |
| SG10201603721TA (en) | 2016-05-10 | 2017-12-28 | Agency Science Tech & Res | Anti-CTLA-4 Antibodies |
| GB201619648D0 (en) | 2016-11-21 | 2017-01-04 | Alligator Bioscience Ab | Novel antibodies and uses thereof |
| KR20240017409A (ko) | 2017-04-13 | 2024-02-07 | 아게누스 인코포레이티드 | 항-cd137 항체 및 이의 사용 방법 |
| RU2019138067A (ru) | 2017-05-02 | 2021-06-02 | Эллигейтор Биосайенс Аб | Биспецифическое антитело против ox40 и ctla-4 |
| JP7173993B2 (ja) * | 2017-05-19 | 2022-11-17 | ウーシー バイオロジクス（シャンハイ）カンパニー リミテッド | 細胞傷害性ｔリンパ球関連タンパク質４（ｃｔｌａ－４）に対する新規モノクローナル抗体 |
| GB201712032D0 (en) | 2017-07-26 | 2017-09-06 | Bioinvent Int Ab | Antibodies and uses thereof |
| WO2019036855A1 (en) | 2017-08-21 | 2019-02-28 | Adagene Inc. | Anti-cd137 molecules and use thereof |
| NZ761785A (en) | 2017-08-21 | 2025-11-28 | Adagene Inc | Dynamic human antibody light chain libraries |
| IL272696B2 (en) | 2017-08-21 | 2025-01-01 | Adagene Inc | Dynamic human heavy chain antibody libraries |
| WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| WO2019148444A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
-
2018
- 2018-02-02 WO PCT/CN2018/075064 patent/WO2019148444A1/en not_active Ceased
-
2019
- 2019-02-01 US US16/265,946 patent/US11359016B2/en active Active
- 2019-02-02 SG SG11202007160PA patent/SG11202007160PA/en unknown
- 2019-02-02 MX MX2020008075A patent/MX2020008075A/es unknown
- 2019-02-02 KR KR1020257027245A patent/KR20250131831A/ko active Pending
- 2019-02-02 AU AU2019214188A patent/AU2019214188B2/en active Active
- 2019-02-02 BR BR112020015385-0A patent/BR112020015385B1/pt active IP Right Grant
- 2019-02-02 JP JP2020541916A patent/JP7413265B2/ja active Active
- 2019-02-02 EP EP19748085.8A patent/EP3746486A4/en active Pending
- 2019-02-02 KR KR1020207024942A patent/KR102848310B1/ko active Active
- 2019-02-02 CA CA3089795A patent/CA3089795A1/en active Pending
- 2019-02-02 WO PCT/CN2019/074580 patent/WO2019149281A1/en not_active Ceased
- 2019-02-02 CN CN201980022531.1A patent/CN112352000B/zh active Active
- 2019-02-02 CN CN202510230988.9A patent/CN120230212A/zh active Pending
- 2019-02-02 US US16/966,844 patent/US11692036B2/en active Active
- 2019-06-10 TW TW108119978A patent/TWI829706B/zh active
-
2020
- 2020-07-26 IL IL276277A patent/IL276277A/en unknown
- 2020-07-30 MX MX2025000370A patent/MX2025000370A/es unknown
- 2020-08-24 ZA ZA2020/05259A patent/ZA202005259B/en unknown
-
2023
- 2023-05-18 US US18/320,146 patent/US20240141046A1/en active Pending
- 2023-07-12 AU AU2023204604A patent/AU2023204604B2/en active Active
- 2023-07-18 JP JP2023116602A patent/JP7678841B2/ja active Active
- 2023-08-18 ZA ZA2023/08021A patent/ZA202308021B/en unknown
-
2024
- 2024-06-07 AU AU2024203885A patent/AU2024203885A1/en active Pending
-
2025
- 2025-05-02 JP JP2025076560A patent/JP2025124652A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021511808A5 (enExample) | ||
| CN112352000B (zh) | 抗ctla4抗体及其制备和使用方法 | |
| KR102068600B1 (ko) | Pdl-1 항체, 그 약학적 조성물 및 그 용도 | |
| WO2022171192A1 (en) | Anti-cd3 antibodies and methods of use thereof | |
| CN104411723B (zh) | 结合淋巴细胞活化基因‑3(lag‑3)的抗体的优化及该抗体的用途 | |
| CN121046961A (zh) | 可活化抗体及其制备和使用方法 | |
| JP7710450B2 (ja) | Ｆｃ変異を有するヘテロダイマータンパク質 | |
| JP2019521103A (ja) | 炎症性疾患及び障害の治療におけるｃｄ３２ｂ×ｃｄ７９ｂ結合分子の使用方法 | |
| JP2025511713A5 (enExample) | ||
| JP2021505637A (ja) | 二重特異性ｃｄ１６結合分子、及び疾患の治療におけるその使用 | |
| US20220220219A1 (en) | Affinity maturated tag72 specific single chaing antibodies | |
| JP2021524451A (ja) | 最適化済みｇｐ４１結合分子及びその使用 | |
| KR20240170602A (ko) | 항-cd137 항체 및 이의 제조 및 사용 방법 | |
| CA3221115A1 (en) | Treatment of pd-l1 negative or low expressing cancer with anti-icos antibodies | |
| CN114269784A (zh) | 具有选择性可切割接头的双特异性结合构建体 | |
| US20240392026A1 (en) | Agonistic cd40 antibodies as immune stimulatory agents | |
| CN121263443A (zh) | 抗ctla4抗体及其制备和使用方法 | |
| NZ767462B2 (en) | Anti-ctla4 antibodies and methods of making and using the same | |
| RU2772434C2 (ru) | Способы применения cd32b x cd79b-связывающих молекул при лечении воспалительных заболеваний и расстройств | |
| NZ807606A (en) | Anti-ctla4 antibodies and methods of making and using the same |